Lv21
198 积分 2023-08-03 加入
Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
2小时前
已完结
Prediction of human drug clearance from animal data: Application of the rule of exponents and ‘fu corrected intercept method’ (FCIM)
1个月前
已完结
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations
2个月前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview
2个月前
已完结
Application of Model‐Informed Drug Development in Dose Selection and Optimization for siRNA Therapies
2个月前
已完结
Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
2个月前
已完结
Strategies for successful dose optimization in oncology drug development: a practical guide
5个月前
已完结
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
5个月前
已完结
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework
5个月前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
6个月前
已完结
皖公网安备34019202002308
